The $3,000 test for the first time accurately identifies the signature brain plaques of the debilitating disease.
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
President Obama on Tuesday announced a campaign designed to develop treatments for some of the least understood brain disorders, an effort that could benefit health care giants Eli Lilly and Co. and others.
Roche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.
Researchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
Odds are long that Eli Lilly and Co.’s leading Alzheimer’s drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.